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Protein source and choice of anticoagulant
decisively affect nanoparticle protein corona
and cellular uptake†
S. Schöttler,a,b Katja Klein,a K. Landfestera and V. Mailänder*a,b
Protein adsorption on nanoparticles has been a focus of the field of nanocarrier research in the past few
years and more and more papers are dealing with increasingly detailed lists of proteins adsorbed to a
plethora of nanocarriers. While there is an urgent need to understand the influence of this protein corona
on nanocarriers’ interactions with cells the strong impact of the protein source on corona formation and
the consequence for interaction with different cell types are factors that are regularly neglected, but
should be taken into account for a meaningful analysis. In this study, the importance of the choice of
protein source used for in vitro protein corona analysis is concisely investigated. Major and decisive differ-
ences in cellular uptake of a polystyrene nanoparticle incubated in fetal bovine serum, human serum,
human citrate and heparin plasma are reported. Furthermore, the protein compositions are determined
for coronas formed in the respective incubation media. A strong influence of heparin, which is used as an
anticoagulant for plasma generation, on cell interaction is demonstrated. While heparin enhances the
uptake into macrophages, it prevents internalization into HeLa cells. Taken together we can give the rec-
ommendation that human plasma anticoagulated with citrate seems to give the most relevant results for
in vitro studies of nanoparticle uptake.
Introduction
In the recent decade, the interest in polymeric nanocarriers for
medical applications has gradually increased and accordingly
a plethora of different nanoparticles have been fabricated. In
particular when used as drug vectors in targeted delivery,
nanocarriers could overcome many obstacles of cancer
therapy. The possibility of a precise adjustment of nano-
carriers’ properties enables the development of specialized
vectors. Nevertheless, their application is still impeded by
insufficient knowledge about interactions of nanocarriers with
their biological environment.
One major challenge is the rapid coverage of intravenously
injected nanocarriers with blood proteins which complicates
any prediction of biological outcomes.1–3 This rapidly forming
protein corona dramatically alters the nanocarriers’ physico-
chemical properties including the hydrodynamic size, surface
charge and aggregation behavior. Furthermore, the interaction
with cell membranes and the mechanism of cellular uptake
are controlled by the adsorbed proteins. Therefore, the corona
defines the biological identity of nanoparticles, influencing
cytotoxicity, body distribution and endocytosis into specific
cells.4,5 As it is often stated, when nanocarriers are introduced
into the body, what the cells actually see is the protein
corona.1 Thus, the prediction of nanocarrier cell interactions
is only possible if the protein corona is taken into account.
Apart from the nanocarrier surface properties, the protein
corona composition is highly dependent on the biological
environment. With regard to in vitro studies, experimental
parameters such as cell culture medium,6 protein concen-
tration7 and temperature8 of the protein source are important
factors in nanoparticle protein interactions.
Studies analyzing the protein corona of nanocarriers in
vitro utilize different types of protein sources and many do not
further specify the type used or state reasons for their choice.
Serum and plasma are often used in an interchangeable
manner. The origin of the protein source, i.e. the species from
which blood was drawn or the type of anticoagulant used for
plasma generation is often neglected. If the corona is deter-
mined after incubation in blood plasma, proteins of the coagu-
lation system are often identified.9–11 In contrast, serum is
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depleted of coagulation factors. The group of Mahmoudi has
reported significant variations in the protein pattern of the NP
corona formed in FBS or human plasma but has not shown
proteomics data.12 In a second study they compared protein
adsorption in human plasma samples obtained from patients
with distinct diseases which also significantly affected protein
composition indicating the existence of personalized protein
coronas.13
The present study attempts to further contribute to a better
understanding of the protein corona formation around nano-
carriers in different environments as it is of great importance
for the assessment of biological effects provoked by these evol-
ving nanobioentities. For this purpose, we analyzed the impact
of distinct protein sources as serum and plasma containing
different anticoagulants on NP uptake and protein corona for-
mation. The concentration of serum or plasma necessary to
impair cell uptake was determined. Serum and plasma concen-
trations applied in cell culture affected the internalization of
nanoparticles into different cell types considerably with a
strong reduction of uptake at concentrations as low as 0.5%.
A major impact on protein corona composition and uptake
of PS-NPs into HeLa cells and RAW267.4 macrophages was
determined for distinct protein sources such as FBS, human
serum and human plasma. A strong uptake of nanoparticles
coated with FBS was observed for both cell lines, while human
serum and human citrate plasma impair NP internalization.
The most exciting finding was the opposing uptake of particles
incubated in human heparin plasma. While the particles were
internalized by macrophages, no uptake was observed for
HeLa cells. Further experiments proved that heparin is respon-
sible for this effect.
These significant implications on NP cell interactions
induced by the characteristics of the surrounding environment
underline the importance of a careful choice of experiment
parameters for in vitro protein corona analysis. Highlighting
these effects elicited by different protein sources is crucial to
ensure the comparability of studies and important information
can be gained for future studies.
Results
Influence of the protein source and cell type on NP uptake
As several studies have reported that for distinct nanoparticles
the cell interaction is diminished when proteins are present
in the cell culture medium compared to conditions where no
proteins are present, we first determined what concentration
of protein containing supplement is necessary to decrease the
uptake. Therefore, a model monodisperse, fluorescently
labeled, amino-functionalized polystyrene nanoparticle with a
diameter of 106 nm was prepared by miniemulsion polymeriz-
ation (PS-NH2) and its uptake into HeLa cells was analysed by
flow cytometry, comparing the interaction of nanoparticles
and cells cultured in different concentrations of human
serum and human heparin plasma (Fig. 1). The cells were cul-
tured in serum-free medium for 2 h before the medium was
changed to the indicated protein source concentrations and
the particles were added. The serum dilution reveals that
uptake of PS-NH2 is already reduced by 50% with only 1%
serum present in the cell culture medium. The cells cultured
in a medium containing more than 1% serum barely interna-
lize any NPs. For human heparin plasma the effect is even
stronger. Only 0.5% plasma is enough to reduce the uptake by
98.8%. While the protein composition in serum has been
changed by activating the proteins of the coagulation cascade
and ultimately removing e.g. fibrinogen, we expected that
anticoagulated plasma with different anticoagulants will have
no varying effect on cell uptake. Surprisingly, there was not
only a remarkable difference between distinct sera (FBS versus
human serum (HS)), but also between differently anticoagu-
lated plasmas (Fig. 2). While fetal bovine serum (FBS), the
most common protein source in cell culture, leads to a strong
uptake, human serum (HS) does not allow a detectable uptake
in HeLa cells (Fig. 2a) or even a macrophage cell line (RAW
264.7, Fig. 2b). This can be explained by the fact that FBS is
additionally heat inactivated while human serum (HS) is not
(see Lesniak et al.14).
Most intriguingly human heparin plasma (HHP) and
human citrate plasma (HCP) showed a significant difference
with more uptake in HeLa cells for HCP (Fig. 2a) while this
was completely reversed for the macrophage cell line (Fig. 2b)
with a strong uptake for HHP.
The strong difference in cellular uptake of NPs incubated in
various types of protein sources displayed in Fig. 2 raised the
question whether the effect is triggered by a distinct protein
adsorption pattern of specific proteins. Thus, the composition
of the protein corona was further analysed by SDS-PAGE and
quantitative proteomics with liquid chromatography-mass
spectrometry (LC-MS).
Fig. 1 Impact of human serum and plasma on uptake of PS-NH2 into
HeLa cells. Cellular uptake of PS-NH2 nanoparticles into HeLa cells cul-
tured in medium containing 0.1 to 100% of either human serum (orange)
or human heparin plasma (purple) was analysed by flow cytometry after
2 h incubation. Values are expressed as mean ± SD of triplicates.
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Investigation of the protein corona composition of different
protein sources and anticoagulants
A comparison of hard corona proteins formed around PS-NH2
in FBS, HS, HHP and HCP after separation by centrifugation is
depicted in Fig. 3 (for soft versus hard corona see ref. 15). The
amount of adsorbed proteins was quantified by a colorimetric
protein assay (Fig. 3a). The strongest protein adsorption was
observed in HCP, followed by HHP and HS. The lowest protein
concentration was measured for the FBS samples. The
SDS-PAGE in Fig. 3b shows that the strongest difference in the
protein pattern is seen between FBS and the human samples.
In addition to the strong albumin band ( just above the 62 kDa
marker), the plasma samples (HHP and HCP) exhibit bands
which could be attributed to fibrinogen (see proteomics
results below). Fibrinogen consists of three subunits, the
alpha, beta, and gamma chain, detected at 47, 56, and 63 kDa,
respectively. Here also the high reproducibility of the method
is visually demonstrated by the similarity of the protein
pattern between the three replicates for each protein source.
To further analyze the protein corona samples, label-free
quantitative proteomics by LC-MS analysis was performed. In
total 290 proteins were identified for all samples (4 conditions,
3 biological replicates, 3 technical replicates). The complete
list of identified proteins is shown in Tables S1 and S2.† Fig. 4
outlines the composition of the different protein coronas
around PS-NH2; the majority of proteins was only identified in
very low concentrations and is thus expressed as “Others”. As
already suggested by SDS-PAGE, albumin is the major protein
in all samples. It accounts for 58% of the protein corona
formed in human serum, 46% in the FBS corona and 47% and
39% in the coronas formed in human heparin and citrate
plasma, respectively. Furthermore, the plasma samples
contain considerable amounts of fibrinogen. Adding up the
percentages determined for the three subunits, fibrinogen has
a 39% share in the corona formed in citrate plasma and 22%
in heparin plasma. Additionally, vitronectin and clusterin were
identified as abundant proteins on the NPs after incubation in
all three human samples. With 19% the highest amount of
clusterin was determined for the human serum samples,
whereas the same amount of vitronectin was adsorbed to the
particles in heparin plasma. Interestingly, incubation with FBS
leads to a strong adsorption of (pro-)thrombin and hemo-
globin, although these proteins are not very abundant in pure
FBS.
In conclusion, a significant difference between the bovine
and human samples was detected. This could explain the
increased uptake of PS-NH2 incubated in FBS for both tested
cell types (Fig. 2), especially as a high abundance of (pro)
thrombin on the particle surface has already been linked to an
increased cell interaction.11 Additionally, the overall lower
protein adsorption in FBS (Fig. 3) points towards an enhanced
cell uptake. NPs incubated in human serum bind a higher
amount of clusterin compared to particles incubated in FBS.
This suggests a participation of clusterin in reducing the
uptake of PS-NH2 incubated in human serum into HeLa cells
and macrophages.16 Despite these conclusive results, the
protein patterns formed around the nanocarrier in citrate and
Fig. 2 Influence of different protein sources on uptake of PS-NH2 into HeLa cells and macrophages. Uptake of PS-NH2 into (a) HeLa cells after 4 h
incubation and into (b) RAW264.7 macrophages after 2 h incubation analysed by flow cytometry. Cells were cultured in serum-free medium for 2 h
before cell medium was changed to 100% fetal bovine serum (FBS), human serum (HS), human heparin plasma (HHP) or human citrate plasma (HCP)
directly before NP addition. Values are expressed as mean ± SD of triplicates.
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heparin plasma display a high level of similarity. The promi-
nent difference in macrophage uptake of PS-NH2 incubated in
the two plasma types can thus not be explained adequately by
protein adsorption. The results suggest that besides protein
corona formation the type of anticoagulant used for plasma
generation might play a major role in cell interaction and was
further examined.
Effect of the anticoagulant heparin
As no strong difference between the compositions of the
different protein coronas on PS-NH2 in the two investigated
plasma samples was detected, the part played by the polysac-
charide heparin in nanoparticle–cell interaction was explored.
The highest uptake of the amino functionalized particle was
Fig. 3 Protein adsorption to the surface of PS-NH2 NPs after incubation in different protein sources. PS-NH2 NPs were incubated with FBS, human
serum (HS), human heparin plasma (HHP) or human citrate plasma (HCP) for 1 h at 37 °C and hard corona proteins were prepared by centrifugation.
(a) Quantification of adsorbed proteins with Pierce 660 nm assay in mg protein per NP surface area (m2). Values are expressed as mean ± SD of the
three biological replicates. (b) SDS-PAGE was used to visualize the protein corona (PC) composition formed around PS-NH2 NPS in the different
protein sources. To guarantee reproducibility, the analysis was performed in triplicates.
Fig. 4 Composition of the protein corona of PS-NH2 NPs after incubation with FBS, HS, HHP or HCP determined by quantitative LC-MS. Mean
values were calculated from the molar masses of each protein for three biological and three technical replicates. Only the six most abundant pro-
teins of each protein corona are shown separately, the amount of remaining proteins was summed up as others.
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detected for FBS for both investigated cell lines. Therefore,
FBS was used as a reference to monitor the effect of heparin.
Fig. 5 shows the uptake of PS-NH2 into HeLa cells and macro-
phages maintained in FBS or heparin plasma as already seen
in Fig. 2, but this time the cells were additionally incubated in
FBS supplemented with heparin. Heparin was added at the
same concentration (17 IU ml−1) as commonly applied in BD
Vacutainer® Plasma Tubes for heparin plasma generation.
Strikingly, uptake of PS-NH2 in FBS containing heparin was
almost completely inhibited compared to uptake in pure FBS.
The internalization is reduced to the same extent as by
heparin plasma. In contrast, the mixture of FBS and heparin
strongly enhances the uptake into macrophages (Fig. 5b). This
is in agreement with the fact that uptake of the particles incu-
bated in heparin plasma is also significantly higher than for
particles in human serum or citrate plasma.
At this point, there are a number of different scenarios for
the role played by heparin. For instance, the polysaccharide
could either adsorb to the nanoparticles or directly bind to the
cells and alter the cellular behavior without being adsorbed to
the nanoparticle. In order to pinpoint this question, in a next
step the particles were either incubated with FBS alone or FBS
supplemented with heparin (Fig. 6). Unbound proteins and
heparin were then removed by centrifugation and the coated
NPs were added to HeLa cells, thus no free heparin was
present. Additionally, the FBS coated particles were added to
the cells cultured in a medium containing heparin. It was
assumed that in this way a distinction between the interaction
of heparin with the particles and an interaction with the cells
was possible. Nevertheless, in both cases, uptake of PS-NH2
was prevented. NPs pre-coated with FBS and subsequently
added to cells cultured in a medium containing heparin and
NPs coated with FBS and heparins were not internalized by
HeLa cells.
These intriguing results raised further questions. Can
heparin alone inhibit particle uptake or are the proteins
present in FBS necessary for the effect? This question was
addressed in the following experiment depicted in Fig. 7. First,
PS-NH2 particles were added to HeLa cells cultured in a cell
culture medium without proteins, a cell culture medium con-
taining FBS alone, and a cell culture medium containing
heparin alone or both (Fig. 7a). The flow cytometry analysis
shows that only the combination of FBS and heparin prevents
the uptake of particles into HeLa cells. Heparin alone does not
have a significant effect on particle internalization.
Does heparin prevent endocytosis of HeLa cells in general?
Therefore the uptake of AF488-dextran was analysed under the
same conditions. Tracing the internalization of fluorescent
dextran is a standard method to monitor endocytosis. Fig. 7b
illustrates that heparin has no influence on dextran uptake.
Thus heparin does not prevent macropinocytosis of HeLa cells
in general but only affects nanoparticle uptake while it seems
Fig. 5 Influence of heparin on uptake of PS-NH2 into HeLa cells and macrophages. Uptake of PS-NH2 into (a) HeLa cells after 4 h incubation and
into (b) RAW264.7 macrophages after 2 h incubation analysed by flow cytometry. Cells were cultured in serum-free medium for 2 h before cell
medium was changed to 100% fetal bovine serum (FBS), human heparin plasma (HHP) or FBS supplemented with heparin (17 IU ml−1) directly before
NP addition. Values are expressed as mean ± SD of triplicates.
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to be adsorbed to the nanoparticle. Considering these two
results together we conclude that heparin alters the uptake of
cargo when it is bound to the surface of the cargo, i.e. the
nanoparticle.
Discussion
This study addresses several parameters which are often neg-
lected when analyzing interactions of nanocarriers, proteins
and cells, such as protein concentration, protein source,
different anticoagulants and cell type. Our results reveal
important differences for the protein corona formation and NP
uptake dependent on the protein source, emphasizing that the
formation of different bionanostructures exerts different bio-
logical effects.
The results presented indicate that, in general, proteins
attenuate the uptake of polystyrene nanoparticles into cells.
Related results have been reported by Lesniak et al., showing a
reduced uptake of polystyrene nanoparticles when proteins are
present in the cell culture medium.17 Furthermore, we show
that the concentration of the protein source has deep impli-
cations on particle uptake. Serum and plasma concentrations
as low as 0.5% already have a major impact by strongly redu-
cing the internalization of an amino-functionalized poly-
styrene nanoparticle into HeLa cells. This should be taken into
Fig. 6 Uptake of PS-NH2 into HeLa cells after incubation with HHP, FBS
or FBS and heparin (17 IU ml−1). NPs were incubated with protein
sources for 1 h at 37 °C and centrifuged to remove residual proteins
before NPs were added to cells cultured in pure DMEM (green) or
DMEM supplemented with heparin (17 IU ml−1; purple). Uptake was ana-
lysed by flow cytometry after 2 h incubation. Values are expressed as
mean ± SD of triplicates.
Fig. 7 Effects of heparin on uptake of PS-NH2 and dextran into HeLa cells. Uptake of (a) PS-NH2 and (b) AF488-dextran (100 µg ml
−1) into HeLa
cells was analysed by flow cytometry after 2 h incubation. Cells were cultured in serum-free medium for 2 h before cell medium was changed to
pure DMEM (control), DMEM containing either 10% FBS, heparin (17 IU ml−1) or both. Values are expressed as mean ± SD of duplicates.
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account in all experiments investigating cellular uptake of
nanocarriers. In order to adjust in vitro experiments to be as
close as possible to in vivo conditions, it should be considered
to use 100% of the respective protein source as this is the
natural concentration in vivo. However, no large discrepancies
between 10%, the concentration most commonly used for cell
culture experiments, and 100% were observed for particle cell
interactions.
Most importantly, it was demonstrated that the choice of the
protein source is crucial for nanoparticle uptake analysis. Many
recent studies of great importance investigating the different
aspects of the protein corona of nanocarriers employed
different protein sources as FBS,17,18 human serum,19,20 human
citrate3,21 or EDTA plasma2,22 without further stating reasons
for their choice. The results shown here emphasize the neces-
sity of a careful decision concerning the protein source as the
outcome of experiments is strongly dependent on it.
Hard corona protein profiles varied significantly between
the investigated protein sources: FBS, human serum, human
heparin and citrate plasma. A strong difference in corona com-
position was especially prominent between the human and
bovine media. As FBS is the most frequently used supplement
for many cells cultured in vitro, it is also often employed in
protein corona studies. But in order to obtain a significant
improvement in the prediction of the in vivo fate of nano-
particles, it is important to test the protein corona formation
in the respective medium i.e. the exact protein source of the
desired species (e.g. murine or human) before applying nano-
carriers in vivo.
Furthermore, the distinction between plasma and serum is
often neglected. A rather strong adsorption of fibrinogen to
nanoparticles from both plasma samples was observed and
might affect nanoparticle uptake substantially. As fibrinogen
is not present at large in serum as it has been clotted to fibrin,
this is a huge and important difference. Thus the distinction
should not be ignored.
On the other hand, anticoagulants used for plasma gene-
ration can bias the observations significantly. During plasma
preparation from whole blood, blood clotting is prevented
either by EDTA, citrate or heparin. EDTA and citrate are both
effective by calcium complexation and thus do not change the
protein composition. Heparin binds to antithrombin III (ATIII)
and increases its activity in blocking thrombin and therefore
inhibits fibrin clot formation. Most importantly ATIII is not
detected or below 1% of total protein of the protein corona
formed for the plasma samples.
In their publication analyzing the uptake of polystyrene
nanoparticles into different types of white blood cells
Baumann et al. have already described the influence of EDTA
on endocytosis.23 They report a dramatically reduced uptake of
carboxy and amino-functionalized nanoparticles into CD14+
monocytes and CD16+ neutrophil granulocytes when EDTA or
citrate was used instead of heparinized blood. Therefore, it
was concluded that EDTA is hindering the uptake by complex-
ing calcium, as calcium is needed as a signaling messenger in
phagocytosis.
The present study further investigates the effect of heparin
and it was shown that heparin enhances uptake into
macrophages and even more strikingly inhibits the uptake of
nanoparticles into HeLa cells. Heparin is a natural glyco-
saminoglycan composed of repeating disaccharide units con-
sisting of uronic acid and D-glucosamine. It is most commonly
known as an anticoagulant and has been used as a drug since
the 1930s. In addition to its well investigated anticoagulant
activity, heparin is involved in diverse physiological processes
including cell proliferation, differentiation, inflammation,
angiogenesis and viral infectivity through interacting with a
large range of proteins.24 It also exerts anticancer activities in
the processes of tumor progression and metastasis.25 Still,
usually heparin is stored within the secretory granules of mast
cells and released only into the vasculature at sites of tissue
injury.24 With its high content of sulpho and carboxyl groups,
heparin has the highest negative charge density of any known
biological molecule.26
Binding of highly negatively charged heparin to the nano-
particle surface might cause an unfavorable interaction
between the nanoparticles and the negatively charged cell
membrane. Accordingly, numerous studies have shown that
the surface charge has a significant impact on cellular intern-
alization of a variety of nanocarriers. Positively charged nano-
particles reveal a high rate of internalization into HeLa cells,
whereas negatively charged NPs exhibit a poor rate of
endocytosis.27–29
Nevertheless, reported effects of heparin on cellular uptake
of nanomaterials are quite controversial. As heparin has been
shown to inhibit complement activation,30–32 binding of
heparin to surfaces has been suggested as an alternative for
PEGylation in a biomimetic approach. Heparin immobilized to
the surface of nanocarriers can mimic eukaryotic cells that are
naturally covered with glycosaminoglycans, thus concealing
the unnatural nanoparticles from the immune system. Accord-
ingly, several manuscripts report a prolonged blood circulation
of nanoparticles coated with heparin.33–35 Furthermore,
heparin has proven its ability to inhibit the adsorption and the
internalization of nanoparticles by a murine macrophage-like
cell line in vitro.36
On the other hand, a high uptake of heparin-based nano-
capsules into different tumor cell lines was described,37 as
well as an enhanced uptake of heparin functionalized PLGA-
based nanoparticles into a fibroblast and tumor cell line.38 In
our study we have seen an enhanced uptake into macrophages
when heparin is present, but an inhibition into the cancer cell
line HeLa. Clearly the difference between these approaches
and ours is the type of cell used and also the way the heparin
has been bound or in our case adsorbed to the particles.
Up to now, the mechanism of this process is unclear. Inter-
estingly, proteins seem to be necessary for this effect as
heparin alone does not prevent the uptake of PS-NPs into
HeLa cells. Proteins present in FBS are sufficient to provoke
the reduced uptake and the high amount of coagulation pro-
teins only present in plasma is not necessary. Furthermore, it
was shown that heparin does not impair the internalization of
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dextran by HeLa cells indicating that a specific interaction of
heparin and the nanocarriers occurs and the adsorbed
heparin leads to decreased uptake while endocytosis by
heparin in medium is not inhibited in general.
The opposing effects of heparin on NP uptake by HeLa cells
and macrophages point to the different mechanisms of entry
into various cells. Different ways of endocytosis utilized by
non-phagocytic cells as HeLa and phagocytes like macro-
phages seem to be relevant for the effect provoked by heparin.
Already in 1983, Bleiberg et al.39 postulated heparin receptors
on mouse macrophages and evidence for a scavenger mediated
uptake into the same macrophage-like cell line used in the
present study (RAW264.7) was published by Falcone six years
later.40 Matching in vivo data further linked liver uptake of
heparin to a scavenger receptor mediated mechanism.41 Fur-
thermore, Lindstedt et al. showed that soluble heparin proteo-
glycans secreted by stimulated mast cells trigger uptake of LDL
by macrophages through scavenger receptor-mediated phago-
cytosis.42 All these reports provide evidence that heparin’s
binding to RAW264.7 cells is mediated by the scavenger recep-
tors and fit the high uptake of nanoparticles incubated with
heparin plasma or FBS supplemented with heparin into
macrophages.
Laurent et al. have already pointed out the key role of the
protein source in the formation of the associated protein
corona and the impact of the cell “observer” effect.12 They
compared the corona composition formed around superpara-
magnetic iron oxide nanoparticles (SPIONs) in FBS and human
plasma (the anticoagulant was not further specified) with
SDS-PAGE and determined significant differences. Furthermore,
cell uptake and toxicity were probed for various cell lines and
the results indicate that each cell type responds differently to
the nanoparticles. Nevertheless, they did not analyze the com-
bined effect of the distinct protein sources and the cell types.
Experimental
Nanoparticle preparation and characterization
The polystyrene nanoparticles were prepared using a modified
protocol as previously described.43 A macroemulsion was pre-
pared with a continuous phase containing cetyltrimethyl-
ammonium chloride solution (CTMA-Cl) (25 wt% in water,
400 mg, 3.1 × 10−4 mol) as the surfactant and 2-aminoethyl
methacrylate hydrochloride (AEMH) (180 mg, 1.1 × 10−3 mol,
3 wt% to styrene, for the introduction of amino functionalities)
in 23.6 g Millipore water and a dispersed phase containing dis-
tilled styrene (5.88 g, 5.7 × 10−2 mol), hexadecane (251 mg,
1.1 × 10−3 mol) as the hydrophobe, Bodipy methacrylate
(9,6 mg, 2.1 × 10−5 mol) as the fluorescent dye and 2,2′-azobis
(2-methylbutyronitrile) (V59) (100 mg, 5.2 × 10−4 mol) as the
oil soluble azo initiator.
Both phases were made homogeneous by mechanical
stirring and the continuous phase was added slowly to the
stirring dispersed phase. The macroemulsion was stirred for
1 h at the highest speed. Subsequently, the macroemulsion
was ultrasonicated with a Branson Sonifier (1/2″ tip, 6.5 nm
diameter) for 2 min at 450 W 90% amplitude under ice
cooling to obtain a miniemulsion. The miniemulsion was
directly transferred into a 50 mL flask and stirred in an oil
bath at 72 °C. The polymerization was run for 18 h. The dis-
persion was purified by centrifugation (2.5 h, 12 000 rpm;
3 times), the supernatant was always removed and the pellet
redispersed in sterile water.
A hydrodynamic particle diameter of 116 nm (±13 nm) was
determined using a NICOMP zetasizer (Agilent Technologies).
The measurement was conducted at 25 °C in a diluted
aqueous dispersion at an angle of 90°. Zeta potential measure-
ments were performed with a Malvern Instruments Zeta Nano-
sizer at a detection angle of 173° in a 10−3 M KCl sample
dispersion. A ξ-potential of 42.8 mV was determined for the
amino functionalized polystyrene nanoparticles.
Plasma and serum samples
Whole blood was taken at the Department of Transfusion
Medicine Mainz from healthy donors after physical examin-
ation and after obtaining informed consent in accordance
with the Declaration of Helsinki. For human serum gene-
ration, blood was clotted overnight according to a standard
procedure and serum from seven volunteers was pooled into
one batch. Plasma was generated by addition of either citrate
(0.2 ml CPD solution per ml) or Na-heparin (20 IU ml−1) as
anticoagulants and subsequent centrifugation. Human
heparin and citrate plasma from ten and six donors, respect-
ively, was pooled into one batch and all samples were stored
at −80 °C. With Pierce 660 nm protein assay a protein concen-
tration of 69 mg ml−1 was determined for human serum,
66 mg ml−1 for human heparin and citrate plasma. To remove
any aggregated proteins the samples were centrifuged for 1 h
at 20 000g before usage.
Cell culture
Human cervix carcinoma cells (HeLa) and the murine macro-
phage cell line RAW264.7 were cultured in Dulbecco’s modi-
fied eagle medium (DMEM), supplemented with 10% FCS, 100
U per ml penicillin, 100 mg per ml streptomycin and 2 mM
glutamine. All cells were grown in a humidified incubator at
37 °C and 5% CO2.
For the uptake experiments, the cells were seeded at a
density of 20 000 cells per cm2. For the analysis of nanoparticle
internalization under serum-free conditions, the cells were
washed 3 times with PBS and incubated in fresh serum-free
medium for 2 h before the cell medium was exchanged for
100% fetal bovine serum (FBS), human serum (HS), human
heparin plasma (HHP), human citrate plasma (HCP) or FBS
supplemented with heparin (Rotexmedica). Nanoparticle dis-
persions were added at a concentration of 75 µg ml−1 to the
cells and dextran labeled with Alexa Fluor® 488 (Thermo
Fisher Scientific) was added at a concentration of 100 µg ml−1.
Before the cells were analysed by flow cytometry they were
washed to remove free nanoparticles.
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Flow cytometry
For the quantitative analysis of nanoparticle uptake into cells
flow cytometry measurements were conducted. After the indi-
cated incubation time, adherent cells were washed with DPBS
and subsequently detached from the culture vessel with 2.5%
trypsin. Flow cytometry measurements were performed on a
CyFlow ML cytometer with a 488 nm laser for excitation of
Bodipy-1 and a 527 nm band pass filter for emission detection.
Data analysis was performed using FCS Express V4 software by
selecting the cells on a forward/sideward scatter plot, thereby
excluding cell debris. These gated events were further analysed
by the amount of fluorescence signal expressed as a median
intensity. The median intensity of a negative control was sub-
tracted from the obtained values. Mean values and standard
deviation were determined from triplicates.
Protein corona preparation
To ensure reproducibility the ratio of total particle surface area
to plasma concentration was kept at 20 ml m−2. The nano-
particle dispersion was diluted with ultrapure water to a con-
stant particle surface concentration (0.05 m2 in 300 µL) and
this dispersion was incubated with 1 ml plasma or serum for
1 h at 37 °C with constant agitation. The incubation time was
chosen because previous reports confirmed that the protein
corona is formed in a relatively stable manner over a period of
1 h.1 The nanoparticles were separated from the supernatant
by centrifugation at 20 000g for 1 h. The particle pellet was
resuspended in PBS and washed by three centrifugation steps
at 20 000g for 1 h and subsequent redispersion in PBS. Before
the last washing step, the dispersion was transferred into a
fresh protein Lobind tube. Proteins were eluted from the par-
ticles by dissolving the particle–protein pellet in 300 µl urea–
thiourea buffer (7 M urea, 2 M thiourea, 4% CHAPS). Protein
concentrations were determined using Pierce 660 nm protein
assay according to manufacturer’s instructions with BSA as
a standard.
SDS PAGE
For SDS PAGE 16.25 µl of the protein sample was mixed with
6.25 µl NuPAGE LDS sample buffer and 2.5 µl NuPAGE sample
reducing agent and loaded onto a NuPAGE 10% bis–tris
protein gel. The electrophoresis was carried out in NuPAGE
MES SDS running buffer at 150 V for 1.5 h with SeeBlue Plus2
Pre-Stained Standard as a molecular marker. The gel was
stained using SimplyBlue SafeStain according to the instruc-
tion manual.
Liquid-chromatography mass-spectrometry (LC-MS) analysis
Proteins were digested by following the protocol of Hofmann
et al.44 with few modifications. Briefly, 25 µg of each protein
sample were precipitated using the ProteoExtract protein pre-
cipitation kit according to the supplier’s manual. The protein
pellet was resuspended in 100 µl 0.1% RapiGest SF in 50 mM
ammonium bicarbonate and incubated for 15 min at 80 °C.
Dithiothreitol was added to a final concentration of 5 mM
before the sample was incubated at 56 °C for 45 min. Iodoace-
tamide was added to a final concentration of 15 mM and the
samples were kept for 1 h in the dark. Proteins were digested
overnight at 37 °C using trypsin with an enzyme to protein
ratio of 1 : 50. To stop the enzymatic digestions and to degrade
RapiGest SF 2 µl hydrochloric acid were added and the sample
was incubated for 45 min at 37 °C. To remove water immiscible
degradation products of RapiGest SF, the sample was centri-
fuged at 13 000g, for 15 min. For LC-MS analysis the samples
were diluted 10-fold with aqueous 0.1% formic acid and
spiked with 50 fmol µl−1 Hi3 EColi Standard (Waters Corpor-
ation) for absolute quantification.
Quantitative analysis of protein samples was performed
using a nanoACQUITY UPLC system coupled with a Synapt G2-
Si mass spectrometer. Tryptic peptides were separated on the
nanoACQUITY system equipped with a C18 analytical reversed-
phase column (1.7 μm, 75 μm × 150 mm) and a C18 nano-
ACQUITY trap column (5 µm, 180 µm × 20 mm). Samples were
processed with mobile phase A consisting of 0.1% (v/v) formic
acid in water and mobile phase B consisting of acetonitrile
with 0.1% (v/v) formic acid. The separation was performed at a
sample flow rate of 0.3 µl min−1, using a gradient of 2–37%
mobile phase B over 70 min. As a reference compound
150 fmol µl−1 Glu-Fibrinopeptide was infused at a flow rate of
0.5 µl min−1.
Data-independent acquisition (MSE) experiments were per-
formed on the Synapt G2-Si operated in resolution mode. Elec-
trospray ionization (ESI) was performed in positive ion mode
using a NanoLockSpray source. Data was acquired over a range
of m/z 50–2000 Da with a scan time of 1 s, ramped trap col-
lision energy from 20 to 40 V with a total acquisition time of
90 min. All samples were analysed in triplicates. Data acqui-
sition and processing were carried out using MassLynx 4.1.
Data processing and protein identification
Progenesis QI for proteomics was used to process data and
identify peptides. Continuum LC-MS data were post acqui-
sition lock mass corrected. Noise reduction thresholds for low
energy, high energy and peptide intensity were fixed at 120, 25,
and 750 counts, respectively. During database searches, the
protein false discovery rate was set at 4%. The generated
peptide masses were searched against a reviewed human
protein sequence database downloaded from Uniprot. For
samples originating from FBS a reviewed bovine database was
used. Sequence information of Hi3 Ecoli standard (chaperone
protein ClpB) was added to the database to conduct absolute
quantification.45,46 The following criteria were used for the
search: one missed cleavage, maximum protein mass 600 kDa,
fixed carbamidomethyl modification for cysteine and variable
oxidation for methionine. For identification a peptide was
required to have at least three assigned fragments and a
protein was required to have at least two assigned peptides
and five assigned fragments. Identified peptides with score
parameters less than 4 were generally rejected. Quantitative
data were generated based on the TOP3/Hi3 approach, provid-
ing the amount of each protein in fmol.47
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Conclusions
The results presented here, prove that the same protein source
can have a very different impact on distinct cell types and that
not only serum versus plasma is important but also the influ-
ence of the employed anticoagulant is of utmost importance
and a factor which should be taken into account. From our
results citrate anticoagulated plasma seems to be the best
source of plasma in regard to adsorption of plasma proteins
onto surfaces without which the anticoagulant itself would
have an influence on cell uptake.
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